Author Archives: Vijaya Iyer, PhD

FDA Grants Experimental Therapy ACE-083 Fast Track Status for CMT

Investigational therapy ACE-083 was granted fast track designation for Charcot-Marie-Tooth disease (CMT) by the United States Food and Drug Administration, Acceleron Pharma recently announced. ACE-083 can prevent muscle shrinkage or atrophy that cause the debilitating symptoms of CMT disease by blocking the transforming growth…

CMT Awareness Month Celebrated With Events Throughout September

Patient stories are a central theme for the events organized by the Charcot-Marie-Tooth Association (CMTA), Hereditary Neuropathy Foundation (HNF) and others this September as part of the 2018 CMT Awareness Month. A degenerative neuromuscular condition, CMT, affects one in every 2,500 people. It has no known cure. The…